Cargando…

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET. The expression of PAK4 and NAMPT was found to be highe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mpilla, Gabriel, Aboukameel, Amro, Muqbil, Irfana, Kim, Steve, Beydoun, Rafic, Philip, Philip A., Mohammad, Ramzi M., Kamgar, Mandana, Shidham, Vinod, Senapedis, William, Baloglu, Erkan, Li, Jing, Dyson, Gregory, Xue, Yue, El-Rayes, Bassel, Azmi, Asfar S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966587/
https://www.ncbi.nlm.nih.gov/pubmed/31795447
http://dx.doi.org/10.3390/cancers11121902
_version_ 1783488770349203456
author Mpilla, Gabriel
Aboukameel, Amro
Muqbil, Irfana
Kim, Steve
Beydoun, Rafic
Philip, Philip A.
Mohammad, Ramzi M.
Kamgar, Mandana
Shidham, Vinod
Senapedis, William
Baloglu, Erkan
Li, Jing
Dyson, Gregory
Xue, Yue
El-Rayes, Bassel
Azmi, Asfar S.
author_facet Mpilla, Gabriel
Aboukameel, Amro
Muqbil, Irfana
Kim, Steve
Beydoun, Rafic
Philip, Philip A.
Mohammad, Ramzi M.
Kamgar, Mandana
Shidham, Vinod
Senapedis, William
Baloglu, Erkan
Li, Jing
Dyson, Gregory
Xue, Yue
El-Rayes, Bassel
Azmi, Asfar S.
author_sort Mpilla, Gabriel
collection PubMed
description Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET. The expression of PAK4 and NAMPT was found to be higher in PNET tissue compared to normal cells. PAK4-NAMPT dual RNAi suppressed proliferation of PNET cell lines. Treatment with KPT-9274 (currently in a Phase I trial or analogs, PF3758309 (the PAK4 selective inhibitor) or FK866 (the NAMPT inhibitor)) suppressed the growth of PNET cell lines and synergized with the mammalian target of rapamycin (mTOR) inhibitors everolimus and INK-128. Molecular analysis of the combination treatment showed down-regulation of known everolimus resistance drivers. KPT-9274 suppressed NAD pool and ATP levels in PNET cell lines. Metabolomic profiling showed a statistically significant alteration in cellular energetic pathways. KPT-9274 given orally at 150 mg/kg 5 days/week for 4 weeks dramatically reduced PNET sub-cutaneous tumor growth. Residual tumor analysis demonstrated target engagement in vivo and recapitulated in vitro results. Our investigations demonstrate that PAK4 and NAMPT are two viable therapeutic targets in the difficult to treat PNET that warrant further clinical investigation.
format Online
Article
Text
id pubmed-6966587
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69665872020-02-04 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors Mpilla, Gabriel Aboukameel, Amro Muqbil, Irfana Kim, Steve Beydoun, Rafic Philip, Philip A. Mohammad, Ramzi M. Kamgar, Mandana Shidham, Vinod Senapedis, William Baloglu, Erkan Li, Jing Dyson, Gregory Xue, Yue El-Rayes, Bassel Azmi, Asfar S. Cancers (Basel) Article Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET. The expression of PAK4 and NAMPT was found to be higher in PNET tissue compared to normal cells. PAK4-NAMPT dual RNAi suppressed proliferation of PNET cell lines. Treatment with KPT-9274 (currently in a Phase I trial or analogs, PF3758309 (the PAK4 selective inhibitor) or FK866 (the NAMPT inhibitor)) suppressed the growth of PNET cell lines and synergized with the mammalian target of rapamycin (mTOR) inhibitors everolimus and INK-128. Molecular analysis of the combination treatment showed down-regulation of known everolimus resistance drivers. KPT-9274 suppressed NAD pool and ATP levels in PNET cell lines. Metabolomic profiling showed a statistically significant alteration in cellular energetic pathways. KPT-9274 given orally at 150 mg/kg 5 days/week for 4 weeks dramatically reduced PNET sub-cutaneous tumor growth. Residual tumor analysis demonstrated target engagement in vivo and recapitulated in vitro results. Our investigations demonstrate that PAK4 and NAMPT are two viable therapeutic targets in the difficult to treat PNET that warrant further clinical investigation. MDPI 2019-11-29 /pmc/articles/PMC6966587/ /pubmed/31795447 http://dx.doi.org/10.3390/cancers11121902 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mpilla, Gabriel
Aboukameel, Amro
Muqbil, Irfana
Kim, Steve
Beydoun, Rafic
Philip, Philip A.
Mohammad, Ramzi M.
Kamgar, Mandana
Shidham, Vinod
Senapedis, William
Baloglu, Erkan
Li, Jing
Dyson, Gregory
Xue, Yue
El-Rayes, Bassel
Azmi, Asfar S.
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
title PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
title_full PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
title_fullStr PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
title_full_unstemmed PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
title_short PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
title_sort pak4-nampt dual inhibition as a novel strategy for therapy resistant pancreatic neuroendocrine tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966587/
https://www.ncbi.nlm.nih.gov/pubmed/31795447
http://dx.doi.org/10.3390/cancers11121902
work_keys_str_mv AT mpillagabriel pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT aboukameelamro pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT muqbilirfana pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT kimsteve pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT beydounrafic pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT philipphilipa pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT mohammadramzim pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT kamgarmandana pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT shidhamvinod pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT senapediswilliam pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT balogluerkan pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT lijing pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT dysongregory pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT xueyue pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT elrayesbassel pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors
AT azmiasfars pak4namptdualinhibitionasanovelstrategyfortherapyresistantpancreaticneuroendocrinetumors